Description
An aldose reductase inhibitor that blocks the conversion of glucose to sorbitol (Kis = 7.7 nM and 60 µM, for aldose reductase 2 and 1, respectively); prevents diabetes-induced alterations of the cardiovascular system in 14-day streptozotocin-diabetic rats; impairs the synthesis of PGF2α by human cultured preadipocytes.
Formal name: 3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
Synonyms: ICI 128436|MK-538|Ponalrestat
Molecular weight: 391.2
CAS: 72702-95-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cardiovascular System|Cardiovascular Diseases||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes